Revenue segments as reported by the company.

Waters

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative expenses

Research and development expenses

Purchased intangibles amortization

Asset impairment

Litigation provision

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Waters reports robust Q4 earnings, eyes growth through acquisitions

Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.
Despite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.

Waters Corp reports Q1 revenue growth below expectations, eyes biotech

Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.

Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery

Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.
While challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.
The company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.

Waters expands margins amidst China challenges, eyes service growth

Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.

Waters faces sales decline in Q4 2023, eyes PFAS market

Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.

Waters Corp exceeds EPS guidance, eyes China stimulus for growth

Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.

Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies

Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.
While facing sales declines, the company showcased operational efficiency and strategic focus.
Guidance reflects caution on ex-China markets but highlights opportunities for growth.
Strategic flexibility in debt management and product innovation position the company for long-term success.

Waters Corporation excels in Q3, eyes growth in key markets

Waters Corporation's strong Q3 performance exceeded expectations, driven by sales growth in key sectors and recurring revenue expansion.
Despite challenges like China sales decline and negative sales growth projections, the company remains optimistic about future opportunities.
With a focus on operational excellence, strategic positioning, and market confidence, Waters is poised for continued success and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Waters Corporation (NYSE:WAT ) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Caspar Tudor - Head, Investor Relations Udit Batra - President & Chief Executive Officer Amol Chaubal - Senior Vice President & Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Luke Sergott - Barclays Dan Brennan - TD Cowen Derik De Bruin - Bank of America Matt Sykes - Goldman Sachs Josh Waldman - Cleveland Research Operator Good morning. Welcome to the Waters Corporation Second Quarter 2023 Financial Results Conference Call.

Waters Corporation (WAT) Q2 2023 Earnings Call Transcript

Highlights Sales of $741 million grew 4% as reported and 3% in organic constant currency Strength led by double-digit growth in Industrial and Academic & Government Operational excellence added 230 basis points of gross margin expansion High single-digit organic constant currency growth in the U.S. and Europe was partially offset by Pharma weakness in China Wyatt acquisition ahead of expectations with 2% sales contribution in the quarter MILFORD, Mass. , Aug. 2, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the second quarter of 2023.

Waters Corporation (NYSE: WAT) Reports Second Quarter 2023 Financial Results

News Summary: Reduces the cost of gene therapies by using 3-10x less sample than other methodsi while generating faster results and more drug substance information. XBridge Premier GTx BEH SEC columns and a new multi-attribute quantification method doubles analytical speed, quadruples sensitivity, and increases resolution of target analytes by up to 50%.ii The combination of size exclusion chromatography (SEC) and Wyatt Multi-Angle Light Scattering (MALS) generates key quality and process attributes in characterizing adeno-associated viral (AAVs) vectored gene therapies.

Waters Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications

Waters Corporation operates in a fast-growing industry with multiple tailwinds and has a compelling business model. The life science company is being impacted by the declining R&D spending in the biotech and pharmaceutical industries. The headwinds should be temporary as R&D spending are crucial to the competitive advantages of pharmaceutical companies.

Waters Corporation: Temporary Headwinds Present A Buying Opportunity

MILFORD, Mass. , July 5, 2023 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q2 2023 financial results conference call live on Wednesday, August 2 nd, 2023, at 8:00 a.m.

Waters Corporation Schedules Second Quarter 2023 Earnings Conference Call

News Summary:  Waters and Princeton University signed a multi-year agreement to take on real-world challenges in biologics and materials research. Initial collaboration will bring together Waters scientists with Princeton faculty and students to advance research in drug discovery and development using novel bioseparation techniques.

Waters Corporation and Princeton University Announce Multi-Year Research Collaboration

Agilent Technologies

Illumina

Investors seeking growth often have no choice other than paying up for a stock with strong potential. However, there are some stocks that appear to be trading at low valuations relative to their growth potential.

Medicals Stocks Waters, Agilent, Illumina Show Growth Potential

Harvard Bioscience

Mettler-Toledo

The Zacks Instruments - Scientific industry participants like Harvard Bioscience (HBIO), Mettler-Toledo (MTD) and Waters (WAT) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.

3 Instruments Stocks to Watch From a Prospering Industry

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Why Is Waters (WAT) Down 5.6% Since Last Earnings Report?

News Summary: New resolution enhancement mode (REM) for Waters' multi-reflecting time-of-flight (MRT) mass spectrometer leads to greater specificity and higher sample throughput for metabolomics UPLC™-MS/MS and MS imaging studies. Waters' MRT System is the only commercially available instrument capable of 300,000 full width half maximum (FWHM) resolution, a 3X faster scan rate and parts-per-billion mass accuracy.i Identifies molecules more accurately and reduces false positives leading to faster completion of metabolomics and MS imaging studies.

Waters Boosts Resolution and Triples Scan Speed of SELECT SERIES MRT for Metabolomics and MS Imaging

News Summary: Waters combines the enhanced desorption electrospray ionization (DESI) source with the Xevo TQ Absolute tandem quadrupole mass spectrometer to enable faster and more sensitive targeted pre-clinical MS imaging experiments. 5X more sensitive and 5X faster than discovery-grade quadrupole time-of-flight MS imaging assays.i Enables pharmaceutical development scientists to decide which drug candidates to investigate further and develop into marketable drugs as quickly as possible.

Waters Takes Targeted, Quantitative Imaging to the Next Level with New DESI Source for the Xevo TQ Absolute System

News Summary: Integration of Sartorius' process scale multi-column chromatography with Waters' process analytical technology to provide robust analytical data for downstream biomanufacturing of mAbs, recombinant proteins, vaccines, and other biologics. Integrated solution to deliver vital analytical data in days, not weeks – and to reduce waste and help lower drug production costs.

Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing

In the first quarter of 2023, eight investing gurus bought shares of Waters Corp. ( WAT , Financial), and only one sold. Why all that interest?

Waters: A Solid Medical Devices Company

MILFORD, Mass. , May 23, 2023 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D.

Waters Corporation to Present at the Jefferies 2023 Healthcare Conference

MILFORD, Mass. , May 16, 2023 /PRNewswire/ -- Waters™ Corporation (NYSE:WAT) today announced it has completed its acquisition of Wyatt Technology, a pioneer and well-recognized leader in innovative light scattering and field-flow fractionation instruments, software, accessories, and services.

Waters Corporation Completes Acquisition of Light Scattering Leader Wyatt Technology

Waters Corporation (NYSE:WAT ) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Caspar Tudor - Head of Investor Relations Udit Batra - President and Chief Executive Officer Geof Wyatt - Chief Executive Officer, Wyatt Technology Cliff Wyatt - President, Wyatt Technology Amol Chaubal - Senior Vice President and Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Derik De Bruin - Bank of America Merrill Lynch Josh Waldman - Cleveland Research Rachel Vatnsdal - JPMorgan Operator Good morning. Welcome to the Waters Corporation First Quarter 2023 Financial Results Conference Call.

Waters Corporation (WAT) Q1 2023 Earnings Call Transcript

Waters' (WAT) first-quarter results reflect softness in the pharmaceutical market and a slowdown in instruments sales.

Waters (WAT) Q1 Earnings & Sales Miss Estimates, Down Y/Y

Waters (WAT) came out with quarterly earnings of $2.49 per share, missing the Zacks Consensus Estimate of $2.60 per share. This compares to earnings of $2.80 per share a year ago.

Waters (WAT) Lags Q1 Earnings and Revenue Estimates

Highlights First quarter sales of $685 million declined 1% as reported and grew 3% in constant currency Growth in broader Asia and Europe offset by weakness in China and the U.S. Instrument revenues declined 3% in constant currency as Pharma customers recalibrated and delayed spending Recurring revenues grew high-single-digits in constant currency, with continued strength supported by commercial initiatives Strong two-year compound annual sales growth rate of 6.1% as reported and 9.4% in constant currency First Quarter 2023 MILFORD, Mass. , May 9, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the first quarter of 2023.

Waters Corporation (NYSE: WAT) Reports First Quarter 2023 Financial Results

Amphenol

Danaher

Corning

Keysight

QUALCOMM

Jefferies analyst Desh Peramunetilleke says cheap stocks set to benefit from China's rebound include Keysight, Qualcomm, Agilent, Danaher, and Corning.

China-Exposed Stocks Have Rallied, but Bargains Still Exist, Says Analyst

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will hold its Q1 2023 financial results conference call live on Tuesday, May 9th 2023 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters' investor relations website at https://ir.waters.com. A replay of the webcast will also be available until at least May 23rd, 2023, at midnight eastern time.

Waters Corporation Schedules First Quarter 2023 Earnings Conference Call

Waters (WAT) unveils the Xevo TQ Absolute IVD Mass Spectrometer for Clinical Analyte Detection, which enables low-volume clinical sample testing.

Waters (WAT) Expands Portfolio With New Mass Spectrometer

MILFORD, Mass.--(BUSINESS WIRE)-- #life_science_tools--Waters Corporation announced the appointment of former Eaton Corporation executive Richard Fearon to its Board of Directors.

Waters Corporation Appoints Richard Fearon to Board of Directors

Waters (WAT) unveils HPLC System called Alliance iS to strengthen the liquid chromatography instruments business.

Waters (WAT) Launches Alliance iS, Expands HPLC Offerings

Waters is a quality company with a solid track record, stable margins, and increasing revenue growth. The recent weakness in the share price is offering an attractive entry point. The derived historic intrinsic value shows Waters as a serial value compounder and they are expected to continue to create value for shareholders.

News for Waters Stock (WAT)